Andrx to Issue Financial Results for 2005 Fourth Quarter and Full Year and Host Conference Call
March 13 2006 - 2:58PM
Business Wire
Andrx Corporation (NASDAQ:ADRX) today announced that it plans to
issue its 2005 fourth quarter and full year financial results press
release and file its 2005 Form 10-K on Thursday, March 16, 2006,
after the market close. Andrx will then host a conference call on
Friday, March 17, 2006, at 8:00 a.m. ET. This call is being webcast
by CCBN and can be accessed at Andrx's web site at
http://www.andrx.com. The webcast is also being distributed over
CCBN's Investor Distribution Network to both institutional and
individual investors. Individual investors can listen to the call
through CCBN's individual investor center at
http://www.fulldisclosure.com or by visiting any of the investor
sites in CCBN's Individual Investor Network. About Andrx
Corporation We are a pharmaceutical company that: -- develops and
commercializes generic versions of primarily controlled-release
pharmaceutical products, as well as oral contraceptives and
selective immediate-release products; -- distributes pharmaceutical
products, primarily generics, which have been commercialized by
others, as well as our own, primarily to independent and chain
pharmacies and physicians' offices; and -- develops and
manufactures pharmaceutical products for other pharmaceutical
companies, including combination products and controlled-release
formulations. Forward-looking statements (statements which are not
historical facts) in this release are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. For this purpose, any statements contained herein or which
are otherwise made by or on behalf of the Company that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the generality of the foregoing, words
such as "may," "will," "to," "plan," "expect," "believe,"
"anticipate," "intend," "could," "should," "would," "estimate," or
"continue" or the negative other variations thereof or comparable
terminology are intended to identify forward-looking statements.
Investors are cautioned that all forward-looking statements involve
risk and uncertainties, including but not limited to: what
sanctions (including warning letters or a consent decree), if any,
FDA may seek, following its decision to place Andrx on OAI
(Official Action Indicated) status, including without limitation
sanctions relating to any failure to comply with cGMP requirements
and if and when the "hold" on the Company's ANDA approvals will be
lifted, the Company's dependence on a relatively small number of
products, licensing revenues, the timing and outcome of litigation
and future product launches, government regulation, competition,
manufacturing capacities, safety issues, output and quality
processes, recent management appointments and changes and the
potential loss of senior management and other key personnel. Andrx
Corporation is also subject to other risks detailed herein or
detailed from time to time in its filings with the U.S. Securities
and Exchange Commission. Andrx disclaims any responsibility to
update the statements contained herein. This release and additional
information about Andrx Corporation are also available on the
Internet at: http://www.andrx.com.
Andrx (NASDAQ:ADRX)
Historical Stock Chart
From May 2024 to Jun 2024
Andrx (NASDAQ:ADRX)
Historical Stock Chart
From Jun 2023 to Jun 2024